Changes in brain transcripts related to alzheimer's disease in a model of hfe hemochromatosis are not consistent with increased alzheimer's disease risk

Journal of Alzheimer's Disease

Volumn 30, Issue 4, 2012, Pages 791-803

  Johnstone, Daniel M ^a,b,c,d   Graham, Ross M ^e,f,g   Trinder, Debbie ^e,f   Riveros, Carlos ^b,c   Olynyk, John K ^e,f,h,i   Scott, Rodney J ^a,b,c   Moscato, Pablo ^b,c   Milward, Elizabeth A ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g CURTIN UNIVERSITY   (Australia)

^h CURTIN UNIVERSITY   (Australia)

ⁱ FREMANTLE HOSPITAL   (Australia)

Author keywords

Amyloid protein precursor; hemochromatosis; HFE; iron; notch signaling; secretase

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETA PROTEIN GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOLIPOPROTEIN E GENE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENCEPHALITIS; GAMMA SECRETASE GENE; GENE; GENE EXPRESSION; GROUPS BY AGE; HEMOCHROMATOSIS; HUNTINGTON CHOREA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NOTCH RECEPTOR GENE; OXIDATIVE STRESS; PARKINSON DISEASE; PRESENILIN 1 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEX DIFFERENCE; TAU PROTEIN GENE;

EID: 84863003149     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-112183     Document Type: Article

References (83)

1. Moos T, Morgan EH (2004) The metabolism of neuronal iron and its pathogenic role in neurological disease: Review. Ann N Y Acad Sci 1012, 14-26.
2. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873.
3. Madsen E, Gitlin JD (2007) Copper and iron disorders of the brain. Annu Rev Neurosci 30, 317-337.
4. Johnstone D, Milward EA (2010) Molecular genetic approaches to understanding the roles and regulation of iron in brain health and disease. J Neurochem 113, 1387-1402.
5. Burn J, Chinnery PF (2006) Neuroferritinopathy. Semin Pediatr Neurol 13, 176-181.
6. Gregory A, Polster BJ, Hayflick SJ (2009) Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 46, 73-80.
7. LeVine SM (1997) Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 760, 298-303.
8. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott RJ, Chorney M (2001) Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis 3, 471-477.
9. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J (2000) In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57, 47-53.
10. House MJ, St Pierre TG, Kowdley KV, Montine T, Connor J, Beard J, Berger J, Siddaiah N, Shankland E, Jin LW (2007) Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer's disease patients. Magn Reson Med 57, 172-180.
11. Collingwood JF, Chong RK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE, Perry G, Posfai M, Siedlak SL, Simpson ET, Smith MA, Dobson J (2008) Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J Alzheimers Dis 14, 235-245.
12. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK (2008) Clinical perspectives on hereditary hemochromatosis. Crit Rev Clin Lab Sci 45, 451-484.
13. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E,WolffRKet al. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13, 399-408.
14. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC (2008) The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 7, 205-214.
15. West AP Jr, Bennett MJ, Sellers VM, Andrews NC, Enns CA, Bjorkman PJ (2000) Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 275, 38135-38138.
16. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, SoutheyMC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM (2008) Ironoverload-related disease inHFEhereditary hemochromatosis. N Engl J Med 358, 221-230.
17. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR (2006) Screening for hereditary hemochromatosis: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 145, 209-223.
18. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE.(2004) Evolution of untreated hereditary hemochromatosis in the Busselton population: A 17-year study. Mayo Clin Proc 79, 309-313.
19. Adams PC, Passmore L, Chakrabarti S, ReboussinDM,Acton RT, Barton JC, McLaren GD, Eckfeldt JH, Dawkins FW, Gordeuk VR, Harris EL, Leiendecker-Foster C, Gossman E, Sholinsky P (2006) Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 4, 918-923.
20. Berg D, Hoggenmuller U, Hofmann E, Fischer R, Kraus M, Scheurlen M, Becker G (2000) The basal ganglia in haemochromatosis. Neuroradiology 42, 9-13.
21. Nielsen JE, Jensen LN, Krabbe K (1995) Hereditary haemochromatosis: A case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 59, 318-321.
22. Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA, Finn JP, Villablanca P, Laub G, Altshuler LL, Geschwind DH, Mintz J, Neely E, Connor JR (2010) Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 20, 333-341.
23. Moos T, Morgan EH (2002) A morphological study of the developmentally regulated transport of iron into the brain. Dev Neurosci 24, 99-105.
24. Deane R, Zheng W, Zlokovic BV (2004) Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem 88, 813-820.
25. Johnstone D, Milward EA (2010) Genome-wide microarray analysis of brain gene expression in mice on a short-term high iron diet. Neurochem Int 56, 856-863.
26. Golub MS, Germann SL, Araiza RS, Reader JR, Griffey SM, Lloyd KC (2005) Movement disorders in the Hfe knockout mouse. Nutr Neurosci 8, 239-244.
27. Knutson MD, Levy JE, Andrews NC, Wessling-Resnick M (2001) Expression of stimulator of Fe transport is not enhanced in Hfe knockout mice. J Nutr 131, 1459-1464.
28. Moos T, Trinder D, MorganEH(2000) Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. Cell Mol Biol (Noisy-le-grand) 46, 549-561.
29. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF,McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE (2003) Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 12, 23-32.
30. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J,VanVoorstW, Ramic D,Williams J, Goate A, Hardy J, Owen MJ (1999) A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8, 237-245.
31. Collins JS, Perry RT, Watson B Jr, Harrell LE, Acton RT, Blacker D, Albert MS, Tanzi RE, Bassett SS, McInnis MG, Campbell RD, Go RC (2000) Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: The NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 96, 823-830.
32. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD (2004) Synergy between the C2 allele of transferrin and theC282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 41, 261-265.
33. Lehmann DJ, Schuur M,Warden DR, Hammond N, Belbin O, Kolsch H, Lehmann MG,Wilcock GK, Brown K, Kehoe PG, Morris CM, Barker R, Coto E, AlvarezV, Deloukas P, Mateo I, Gwilliam R, Combarros O, Arias-Vasquez A, Aulchenko YS, Ikram MA, Breteler MM, van Duijn CM, Oulhaj A, Heun R, Cortina-Borja M, Morgan K, Robson K, Smith AD (2012) Transferrin and HFE genes interact in Alzheimer's disease risk: The Epistasis Project. Neurobiol Aging 33, 202; e201-e213.
34. Kauwe JS, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, Morris JC, Goate AM (2010) Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am JMed Genet B Neuropsychiatr Genet 153B, 955-959.
35. Moalem S, Percy ME, Andrews DF, Kruck TP,Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC (2000) Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93, 58-66.
36. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C (2001) The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 22, 563-568.
37. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C, Piazza G, Colonna-Romano G, Grimaldi LM, Caruso C (2003) Association between the HFE mutations and unsuccessful ageing:Astudy in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 124, 525-528.
38. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA,MarkesberyWR(2003) Association ofHFEmutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 119B, 48-53.
39. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM (2004) Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 25, 465-474.
40. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, Oliveira C (2006) Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 6, 24.
41. Correia AP, Pinto JP, Dias V, Mascarenhas C, Almeida S, Porto G (2009) CAT53 and HFE alleles in Alzheimer's disease: A putative protective role of the C282Y HFE mutation. Neurosci Lett 457, 129-132.
42. Percy M, Moalem S, Garcia A, Somerville MJ, Hicks M, Andrews D, Azad A, Schwarz P, Zavareh RB, Birkan R, Choo C, Chow V, Dhaliwal S, Duda V, Kupferschmidt AL, Lam K, Lightman D, Machalek K, Mar W, Nguyen F, Rytwinski PJ, Svara E, Tran M, Wheeler K, Yeung L, Zanibbi K, Zener R, Ziraldo M, Freedman M (2008) Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-SUPPL.emented Ontario population. J Alzheimers Dis 14, 69-84.
43. Alizadeh BZ, Njajou OT, Millan MR, Hofman A, Breteler MM, van Duijn CM (2009) HFE variants, APOE and Alzheimer's disease: Findings from the population-based Rotterdam study. Neurobiol Aging 30, 330-332.
44. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG (2007) Hemochromatosis genotypes and risk of 31 disease endpoints: Meta-analyses including 66,000 cases and 226,000 controls. Hepatology 46, 1071-1080.
45. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, Prass CE, Schatzman RC, O'Neill R, Britton RS, Bacon BR, Sly WS (1998) HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 95, 2492-2497.
46. Fleming RE, Holden CC, Tomatsu S, Waheed A, Brunt EM, Britton RS, Bacon BR, Roopenian DC, SlyWS(2001) Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 98, 2707-2711.
47. Bender R, Lange S (2001) Adjusting for multiple testing- when and how? J Clin Epidemiol 54, 343-349.
48. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1, 43-46.
49. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
50. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3.
51. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550.
52. Johnstone D, Graham RM, Trinder D, Delima RD, Riveros C, Olynyk JK, Scott RJ, Moscato P, Milward EA (2012) Brain transcriptomic perturbations in the Hfe?/? mouse model of genetic iron loading. Brain Res, 1448, 144-152.
53. Pardossi-Piquard R, Yang SP, Kanemoto S, Gu Y, Chen F, Bohm C, Sevalle J, Li T, Wong PC, Checler F, Schmitt-Ulms G, St George-Hyslop P, Fraser PE (2009) APH1 polar transmembrane residues regulate the assembly and activity of presenilin complexes. J Biol Chem 284, 16298-16307.
54. Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H (2004) Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 279, 41340-41345.
55. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3, 85-97.
56. Grupe A, Abraham R, LiY, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O'Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J (2007) Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16, 865-873.
57. Poduslo SE, Huang R, Huang J, Smith S (2009) Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B, 50-55.
58. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 39, 17-23.
59. Beutler E (2006) Hemochromatosis: Genetics and pathophysiology. Annu Rev Med 57, 331-347.
60. Pietrangelo A (2004) Hereditary hemochromatosis -A new look at an old disease. New Engl J Med 350, 2383-2397.
61. O'Neil J, Powell L (2005) Clinical aspects of hemochromatosis. Semin Liver Dis 25, 381-391.
62. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16, 693-704.
63. Bruce DG, Davis WA, Casey GP, Starkstein SE, Clarnette RM, Foster JK, Almeida OP, Davis TM (2008) Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 51, 241-248.
64. Lathia JD, Mattson MP, Cheng A (2008) Notch: From neural development to neurological disorders. J Neurochem 107, 1471-1481.
65. Selkoe D, Kopan R (2003) Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26, 565-597.
66. Yang LT, Nichols JT, Yao C, Manilay JO, Robey EA, Weinmaster G (2005) Fringe glycosyltransferases differentially modulate Notch1 proteolysis induced by Delta1 and Jagged1. Mol Biol Cell 16, 927-942.
67. Fischer A, Gessler M (2007) Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35, 4583-4596.
68. Giniger E (1998) A role for Abl in Notch signaling. Neuron 20, 667-681.
69. Hurlbut GD, Kankel MW, Artavanis-Tsakonas S (2009) Nodal points and complexity of Notch-Ras signal integration. Proc Natl Acad Sci U S A 106, 2218-2223.
70. Maekawa M, Ishizaki T, Boku S,Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K, Narumiya S (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285, 895-898.
71. De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8, 141-146.
72. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B (2005) Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 280, 30797-30806.
73. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
74. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL (1992) The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9, 129-137.
75. Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters CL, Nurcombe V (1999) Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J Alzheimers Dis 1, 275-285.
76. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491.
77. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ 3rd, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36.
78. Struhl G, Greenwald I (2001) Presenilin-mediated transmembrane cleavage is required for Notch signal transduction in Drosophila. Proc Natl Acad Sci U S A 98, 229-234.
79. Brunkan AL, Goate AM (2005) Presenilin function and gamma-secretase activity. J Neurochem 93, 769-792.
80. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12.
81. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857-867.
82. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK,Tanzi RE, Bush AI, GiordanoT, GullansSR(2002) An iron-responsive element type II in the 5-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277, 45518-45528.
83. Milward EA, Bruce DG, KnuimanMW,Divitini ML, Cole M, Inderjeeth CA, Clarnette RM, Maier G, Jablensky A, Olynyk JK (2010) A cross-sectional community study of serum iron measures and cognitive status in older adults. J Alzheimers Dis 20, 617-623.